KML001, a Telomere-Targeting Drug, Sensitizes Glioblastoma Cells to Temozolomide Chemotherapy and Radiotherapy through DNA Damage and Apoptosis
Figure 5
KML001 showed little in vivo systemic toxicity in the U87MG GBM orthotopic xenograft models. KML001 (2.5 or 5 mg/kg) was orally administrated into U87MG orthotopic xenograft models every day from 1 day after tumor cell implantation. (a) Body weight was measured twice a week until 20 days after tumor cell implantation. (b) The level of AST and ALT was analyzed in mice serum on the 20th day after tumor cell implantation.
